Stockreport

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Apollomics Inc. - Class A Ordinary Shares  (APLM) 
PDF Continued clinical and regulatory progress for the vebreltinib (APL-101) registration-enabling programCompleted patient enrollment for the uproleselan (APL-106) Phase 3 [Read more]